A BH3 Mimetic for Killing Cancer Cells.
Cell
; 165(7): 1560, 2016 Jun 16.
Article
em En
| MEDLINE
| ID: mdl-27315468
ABSTRACT
Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Leucemia Linfocítica Crônica de Células B
/
Aprovação de Drogas
/
Compostos Bicíclicos Heterocíclicos com Pontes
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article